reported that after ACTL treatment in 3 NSCLC patients with brain metastases, the brain metastases completely resolved and the overall survival exceeded 2 years (36); Hong et al.’s study confirmed that ACTL can completely resolve untreated melanoma brain metastases, highlighting ACTL’s unique advantage of precise killing through antigen-specific CTLs (37). This evidence concerns the gene ACAT2 and melanoma.